Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 4/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3071923 | 0.94 | PDE4B (0.37) | RENPDE4BKMT2ASMN1; SMN2NPC1 | |
| SCHEMBL3070875 | 0.92 | PDE4B (0.37) | RENPDE4BKMT2ASMN1; SMN2NPC1 | |
| SCHEMBL3068647 | 0.88 | PDE4B (0.38) | RENPDE4BKMT2ASMN1; SMN2NPC1 | |
| SCHEMBL3072781 | 0.88 | PDE4B (0.38) | RENPDE4BKMT2ASMN1; SMN2NPC1 | |
| SCHEMBL3072664 | 0.87 | GRM5 (0.40) | RENPDE4BSMN1; SMN2NPC1RAB9A | |
| SCHEMBL3072222 | 0.87 | PDE4B (0.37) | RENPDE4BSMN1; SMN2NPC1RAB9A | |
| SCHEMBL3061482 | 0.87 | PDE4B (0.37) | RENPDE4BKMT2ASMN1; SMN2NPC1 | |
| SCHEMBL3072342 | 0.87 | CHRNB2 (0.39) | RENPDE4BSMN1; SMN2NPC1RAB9A | |
| SCHEMBL3070416 | 0.86 | PDE4B (0.37) | RENPDE4BSMN1; SMN2NPC1RAB9A | |
| SCHEMBL3071666 | 0.86 | SMN1; SMN2 (0.37) | RENPDE4BSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | REN 1/4885PDE4B 312/4885KMT2A 3839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.